The best diagnostic biomarkers found in this study were GLO1 and NKX3-1 which individually could distinguish PCa from BPH in the validation cohort with an AUC of 0.726 and 0.645, respectively. This evidence concerns the gene NKX3-1 and benign prostatic hyperplasia.